 | | Vol. 24.26 – 31 July, 2023 |
| |
|
|
| Researchers combined lipid nanoparticle–mRNA formulations and dendritic cell therapy to boost the cancer–immunity cycle via progressive steps to overcome the immunosuppressive tumor microenvironment.
[Nature Nanotechnology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The rational design and combinatorial synthesis of esterase-triggered decationizable quaternium lipid-like molecules was reported to develop new lipid nanoparticles with high delivery efficiency and improved storage stability.
[Advanced Materials] |
|
|
|
| Researchers tested the ability of growth arrest-specific protein 6 (GAS6) based CAR-T-cell to kill pancreatic cancer cell both in vitro and in vivo, and futher evaluated its safety in mice and nonhuman primates.
[Journal of Hematology & Oncology] |
|
|
|
| Investigators developed an all-in-one biomimetic mineralized CRISPR/Cas9 RNA delivery system, that allowed for precise control over the coencapsulation ratio between Cas9 mRNA and multiple sgRNAs, while also exhibiting a high RNA loading capacity.
[ACS Nano] |
|
|
|
| Scientists performed single-cell RNA sequencing and mass cytometry to study the heterogeneity of CAR-natural killer (NK) cells and their in vivo evolution after adoptive transfer, from the phase of tumor control to relapse.
[Science Advances] |
|
|
|
| Researchers explored whether flap structure-specific endonuclease 1 (FEN1) inhibitors combined with CAR-T-cell immunotherapy would have a stronger killing effect on solid tumors.
[Immunology] |
|
|
|
| Investigators demonstrated that nanobody-derived bispecific CAR-T cells significantly improved anti-tumor efficacy in T-lymphoma treatment.
[Molecular Therapy Oncolytics] |
|
|
|
| In vivo efficacy and safety studies using NSG mice and the high-grade serous ovarian cancer cell line OVCAR4 demonstrated a remarkable and specific anti-tumor response at all the CAR-T cell doses used.
[Molecular Cancer Therapeutics] |
|
|
|
| The authors investigated whether a novel bioabsorbable gelatin hydrogel nonwoven fabric could improve subcutaneous islet engraftment.
[Scientific Reports] |
|
|
|
|
| Scientists review the rationale behind CAR T therapy, current challenges faced in oncology, a synopsis of preliminary reports in noncancerous diseases, and a discussion of relevant emerging technologies.
[Nature] |
|
|
|
| Investigators present the state of the art of cell-based therapy in chronic obstructive pulmonary disease (COPD) and discuss clinical trials that have been completed and published.
[European Respiratory Review] |
|
|
|
|
| Invectys, Inc. announced the US FDA has granted Fast Track designation to its revolutionary product, IVS-3001, a CAR-T cell immunotherapy that targets the rarely exploited immune checkpoint and tumor-specific antigen known as HLA-G.
[Invectys, Inc.] |
|
|
|
| Citius Pharmaceuticals, Inc. announced that the US FDA has issued a Complete Response Letter regarding the Company’s Biologics License Application seeking approval for denileukin diftitox.
[Citius Pharmaceuticals, Inc.] |
|
|
|
|
| September 4 – 7, 2023
Surrey, England, United Kingdom |
|
|
|
|
|
| | IRB Barcelona – Barcelona, Spain |
|
|
|
| | Harvard Medical School-Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | NCI Center for Cancer Research – Bethesda, Maryland, United States |
|
|
|
| | University of Cincinnati – Cincinnati, Ohio, United States |
|
|
|
| | NICHD – Bethesda, Maryland, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
